Ankura™ TAA Stent Graft System Post-Market Clinical Follow-up Study

• Patient has descending thoracic aortic aneurysm (DTA) or type B aortic dissection (TBAD), who needs endovascular repair (TEVAR).
• Life expectancy > 1 year.
• Patient or legally authorized representative understands the nature of the clinical trial, agrees to its provisions, agrees to comply with the requirements of the study including a 3-year follow-up, and signed applicable Informed Consent Form.

• Patient's characteristics consistent with Ankura™ Stent Graft System IFU and sizing guidelines, which indicate as following:

  1. For descending thoracic aortic aneurysm (DTA) patient:

     • Adequate iliac/femoral access vessel that is compatible with the required delivery system.
     • Aortic inner diameter in the range of 18-42mm.
     • ≥15mm non-aneurysmal aorta proximal and distal to the lesion.
     • Morphology suitable for endovascular repair.

  2. For type B aortic dissection (TBAD) patient:

     • Adequate iliac/femoral access vessel that is compatible with the required delivery system.
     • ≥15mm landing zone proximal to the primary entry tear; proximal extent of the landing zone must not be dissected. Diameter at proximal extent of proximal landing zone in the range of 16-44mm.
     • ≥15mm landing zone distal to the primary entry tear; distal extent of the landing zone must not be dissected. Diameter at distal extent of distal landing zone in the range of 16-44mm.
     • Morphology suitable for endovascular repair.

Exclusion Criteria:

• Patient with any contraindications mentioned in the Ankura™ Stent Graft System IFU:

  • Patients with acute systemic infection;
  • Patients who have had other devices implanted in the cardiovascular cavity, which will interfere with the placement of this device;
  • Patients with mesenteric blood flow mainly supplied by the inferior mesenteric artery;
  • Patients who have allergic reaction to the device;
  • Patients who are not suitable for endovascular repair in vascular morphology;
  • Patients who cannot tolerate contrast agents due to severe renal insufficiency;
  • Patients who are allergic to contrast agents;
  • Aneurysms neck with thrombus;
  • Non-aneurysmal aortic proximal neck length \<1.5cm;
  • Non-aneurysmal aortic distal anchorage zone \<1.5cm;
  • For aneurysms, Non-aneurysmal aortic diameter \<18mm or >42mm. For Type B dissections, Non-aneurysmal aortic diameter \<16mm or >44mm.
• Patient with traumatic aortic injury;
• Patient with uncorrectable coagulopathy;
• Patient with hereditary connective tissue disease, including but not limited to Marfan Syndrome or Ehlers-Danlos Syndrome;
• Patient with morbid obesity, weight greater than 350 Pounds (150kg), or who cannot undergo accurate fluoroscopy examination due to obesity;
• Age\<18 Years or Age> 85 Years;
• Pregnant or plan to be pregnant or breast feeding;
• Myocardial infarction or stroke within 3 months prior to the procedure;
• American Society of Anesthesiologists Physical Status Classification (ASA) classification 5 or higher;
• Patient with an unstable angina pectoris or hearth insufficiency New York Heart Association Functional Classification (NYHA) 3 or 4
• Participant in other drug or medical device clinical trials;
• Patient with access vessel which are to tortuous, narrow or any kind of reasons that would lead to failure of introduction and advancing an introducer sheath;
• Any condition (medical or anatomic) which makes the patient not suitable for endovascular repair according to the opinion of the investigator.